Foresite Capital Management Iv, LLC Nurix Therapeutics, Inc. Transaction History

Foresite Capital Management Iv, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.88 - $14.82 $2.79 Million - $5.24 Million	-353,655 Reduced 34.31%	677,143 $8.58 Million
Q1 2022 May 13, 2022	SELL	$12.94 - $29.65 $2.26 Million - $5.19 Million	-175,000 Reduced 14.51%	1,030,798 $14.4 Million
Q2 2021 Aug 16, 2021	SELL	$24.21 - $35.89 $790,650 - $1.17 Million	-32,658 Reduced 2.64%	1,205,798 $32 Million
Q1 2021 May 17, 2021	SELL	$26.98 - $50.17 $29.9 Million - $55.7 Million	-1,109,348 Reduced 47.25%	1,238,456 $38.5 Million
Q4 2020 Feb 16, 2021	SELL	$22.85 - $48.44 $4,798 - $10,172	-210 Reduced 0.01%	2,347,804 $77.2 Million
Q3 2020 Nov 13, 2020	BUY	$16.05 - $34.91 $37.7 Million - $82 Million	2,348,014 New	2,348,014 $82 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iv, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iv, LLC with notifications on news.